FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

For patients with HER2+/HR+ early breast cancer, endocrine therapy is recommended in combination with trastuzumab and pertuzumab in both the adjuvant and post-neoadjuvant settings.

The phase 3 trial compares trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) in combination with pertuzumab (Perjeta, Genentech) vs. current first-line standard of care in patients ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

And then for the patients who were taking trastuzumab deruxtecan, you could stop if you had toxicity, and in the pertuzumab arm, add trastuzumab as a maintenance approach.

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive metastatic breast cancer.

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...